# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More T...
Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $8 ...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...
Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $8 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...